It is a reasonable shot in the dark. I think Elite will be successful selling under their own label because the Adderall generic shortage continues, making Elite’s Adderall an easy sell. Once Elite is an approved vendor for the large buyers they can sell the small market products as well. FDA approval is never certain, but I think the Dopamine agonist could be on the market by year end. Any positive news on the “needle movers” could fuel a rally. I think ELTP has started a “drive for five”. My bet is we hit a nickel by fall… maybe even late summer.
News 
Market Data 
Discover 
